August 25, 2016
Salk scientists, in collaboration with Dr. Josep Maria Campistol, CEO and nephrologist of Hospital Clínic and Marta Lazo, IDIBAPS researcher, have managed to create and maintain renal structures through the use of a 3D culture and a new combination of signaling molecules. It is the first time that researchers succeed in maintaining a culture of Nephron Progenitor Cells (NPCs), which is an important boost to translational medicine and to research on the development of kidney disease and a further step towards the possibility of creating a transplantable kidney . The study, led by Dr. Juan Carlos Izpisua Belmonte, professor in Salk's Gene Expression Laboratory, has been published in the journal Cell Stem Cell.
August 5, 2016
A new animal model to study the potential of CD6 receptor as a therapeutic target for immune-mediated diseases
IDIBAPS researchers have developed, for the first time, an animal model to study the role of the CD6 protein, a T lymphocyte molecule involved in the susceptibility for developing autoimmune diseases. It is an animal model, a mouse, that does not express this protein and that will reveal its pathophysiological role in the context of immune-mediated diseases such as Multiple Sclerosis, psoriasis or rheumatoid arthritis. Dr. Francisco Lozano, head of the IDIBAPS team Immune receptors of the innate and adaptive system and Senior Consultant at the Immunology Department in Hospital Clínic, has coordinated the study published in the Journal of Experimental Medicine (JEM).
August 4, 2016
Ramon Gomis explains the beneficial properties of sardines in type II diabetes at "Ciencia After Work"
The last session of Ciencia After Work, held on June, was focused on the beneficial properties of sardines, from a scientific, social and cultural point of view. Entitled 'Sardine network: food, health and sustainability', the scientific conversation that took place at La Pedrera was attended by Dr. Ramon Gomis, Director of IDIBAPS; Toni Massanés, Director of the Alicia Foundation; and Sergi Tudela, General Director for Fisheries and Marine Affairs at the Generalitat.
July 29, 2016
A fat-derived stem cell therapy is effective for the treatment of fistulas in Crohn's disease. A study published today in The Lancet, has shown that the treatment cures this lesions in 50% of patients, even in cases in which all therapeutic alternatives available fail. Thus, patients can avoid surgery. Dr. Julià Panés, Head of the Gastroenterology Department at Hospital Clínic and of the Inflammatory Bowel Disease IDIBAPS research team, is the principal investigator of the study, in which 49 hospitals in Europe and Israel collaborated. Dr. Damián García-Olmo, head of the Department of Surgery at the Hospital Fundación Jiménez Díaz-Quirónsalud Group, has established the surgical protocol for this study. This is the first Phase III study in the world to test cell therapy for fistulas in Crohn's disease.
July 29, 2016
Thaïs Armangué and Mihai Calin Pavel receive two research grants from the Mutua Madrileña Foundation
Mutua Madrileña Foundation presented on July 14th the XIII call of the "Grants for Health Research" funded with 1.7 million euros for 18 projects. Drs. Thaís Armangué, neuropaediatrician at the Experimental Neuroimmunology Unit of IDIBAPS and Hospital Clinic, and Mihai Calin Pavel, from the Department of General and Digestive Surgery at the hospital, have received two of these grants.